Business
Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist
The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated autoimmune indications Allschwil, Switzerland – January 6, 2026Idorsia Ltd (SIX: IDIA) announces the initiation of a Phase 2 proof-of-concept trial evaluating IDOR-1117-2520 for participants with moderate-to-severe psoriasis. IDOR-1117-2520 is Idorsia’s first-in-class, oral, selective CCR6 receptor antagonist designed to block the CCR6/CCL20 axis and prevent the migration
About this update from Idorsia Ltd.
[{"type":"image","alt":"Idorsia Pharmaceuticals Ltd","displaySize":"","headline":null,"caption":"Idorsia Pharmaceuticals Ltd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/atcBYtwjtI326vFfueDYtQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE5MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/78a4ac48860a5805262d0e653fb52e9a","width":300,"height":138}},"lazy":false},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated autoimmune indications","length":148,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":148,"olType":false},{"type":"text","content":"Allschwil, Switzerland – January 6, 2026Idorsia Ltd (SIX: IDIA) announces the initiation of a Phase 2 proof-of-concept trial evaluating IDOR-1117-2520 for participants with moderate-to-severe psoriasis. IDOR-1117-2520 is Idorsia’s first-in-class, oral, selective CCR6 receptor antagonist designed to block the CCR6/CCL20 axis and prevent the migration of disease-driving Th17 immune cells.","length":390,"tagName":"p"},{"type":"text","content":"Psoriasis is a chronic, immune-mediated skin condition driven by the IL-23/Th17 pathway, characterized by elevated CCL20 and CCR6-positive cells in affected skin.1 There is a significant need for oral drugs with innovative mechanisms of action that address Th17-driven conditions such as psoriasis.","length":298,"tagName":"p"},{"type":"text","content":"The 12-week exploratory Phase 2 proof-of-concept trial will evaluate whether CCR6 blockade improves psoriasis by preventing pathogenic immune cells from reaching the skin. Two dosages of the once-daily oral drug will be tested against placebo, using established clinical endpoints such as Psoriasis Area and Severity Index (PASI) and biomarkers including beta-defensin 2, a key indicator of disease activity.2 Psoriasis is a well-validated indication to demonstrate clinical proof-of-mechanism for targeting of the IL-23/Th17 pathway that matches Idorsia’s ambition for its investigational compound.","length":599,"tagName":"p"},{"type":"text","content":"Alberto Gimon...